Table 1.
Clinicopathologic factors for the MD Anderson Cohort (N=3,327)
| Variable | No. of Patients (%) |
|---|---|
|
| |
| Age year | |
| Mean | 58 |
| Median (range) | 57 (25-99) |
|
| |
| Pathologic T stage | |
| T1 | 2,013 (60.5%) |
| T2 | 1,125 (33.8%) |
| T3 | 189 (5.7%) |
|
| |
| Pathologic N stage | |
| N0 | 2,230 (67.1%) |
| N1mic | 180 (5.4%) |
| N1 | 726 (21.8%) |
| N2 | 123 (3.7%) |
| N3 | 65 (2.0%) |
|
| |
| Pathologic Stage | |
| I (A and B) | 1602 (48.1%) |
| IIA | 999 (30.0%) |
| IIB | 467 (14.1%) |
| IIIA | 194 (5.8%) |
| IIIC | 65 (2.0%) |
|
| |
| ER status | |
| Positive | 2,901 (87.2%) |
| Negative | 426 (12.8%) |
|
| |
| PR status | |
| Positive | 2491 (74.9%) |
| Negative | 836 (25.1%) |
|
| |
| HER2 status | |
| Positive | 306 (9.2%) |
| Negative | 3,021 (90.8%) |
|
| |
| Nuclear Grade | |
| 1 | 482 (14.5%) |
| 2 | 1,815 (54.5%) |
| 3 | 1,030 (31.0%) |
|
| |
| Adjuvant chemotherapy | |
| No | 1,651 (50.4%) |
| Yes | 1,624 (49.6%) |
|
| |
| Adjuvant hormonal therapy | |
| No | 612 (18.8%) |
| Yes | 2,648 (81.2%) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor